No specialty in medicine straddles the billing complexity divide quite like dermatology. Your practice operates simultaneously in medical dermatology (diagnosis, disease management, biopsy), surgical dermatology (excisions, Mohs surgery, reconstruction), and increasingly in cosmetic dermatology (non-covered aesthetic procedures with their own billing rules and patient payment protocols). Each world has distinct CPT codes, different documentation standards, separate payer coverage rules, and unique compliance risks. A generalist billing team can't reliably navigate all three — and the revenue losses compound across every service line every day. ParaMed's dermatology-certified billing specialists operate fluently across the full dermatology billing spectrum, capturing every dollar your practice earns in every service category.
Mohs, excisions, destruction, repairs — precise margin & defect billing
E/M, biopsies, patch testing, phototherapy, systemic therapy management
Injectables, laser, body contouring — non-covered patient-pay billing
These aren't edge-case billing errors — they're the systematic revenue failures we find in virtually every dermatology practice that comes to us after working with a generalist billing team. Each one is measurable, preventable, and generating compounding losses every month you don't address it.
Excision CPT codes (11400–11646) are determined by the size of the excised lesion including margins — not the lesion alone. The difference between a 0.5cm and a 0.6cm margin-inclusive diameter can be the difference between two entirely different CPT codes. When billing teams default to the smallest applicable code "to be safe," or measure incorrectly, they systematically under-bill every excision in your practice. Multiply that across 20–40 excisions per week and the annual revenue impact is substantial.
Mohs micrographic surgery bills by stage (17311 for first stage, 17312 for each additional stage) plus reconstruction. When the pathology report documents three stages but only two are billed, the revenue loss is immediate and compounding. More insidiously, when reconstruction following Mohs is performed but billed generically rather than with the specific reconstruction code that reflects the actual technique, practices routinely leave $200–$800 per Mohs case in under-coded reconstruction billing.
The line between cosmetically-motivated and medically necessary dermatology procedures is the sharpest compliance edge in the specialty. Botulinum toxin for cosmetic purposes (non-covered) vs. botulinum toxin for hyperhidrosis (covered with documentation) use different billing pathways. Misclassifying medical procedures as cosmetic results in denied insurance billing; misclassifying cosmetic procedures as medical creates fraud exposure. Both are common without specialty billing expertise.
In 2019, the dermatology biopsy CPT code set was completely restructured — 11100 and 11101 were replaced by a new family (11102–11107) based on biopsy technique (tangential, punch, incisional) rather than just quantity. Many dermatology practices — and virtually all generalist billing teams — still use the pre-2019 codes (which are now deleted), or fail to select the technique-appropriate code from the new family. Using deleted codes creates automatic rejection; using the wrong technique code creates audit exposure.
When a dermatologist performs both an evaluation and management service and a procedure on the same day, the E/M is separately billable — but only with Modifier -25 indicating it was a significant, separately identifiable service above and beyond the pre-service work for the procedure. Without Modifier -25, the E/M is automatically bundled into the procedure under NCCI, and the visit is denied. But Modifier -25 requires documentation that the E/M was genuinely separate — not just the pre-procedure assessment. Missing the modifier, or applying it without sufficient documentation, are both costly errors that affect a high percentage of dermatology claims where both services are performed.
Dermatology practices with cosmetic service lines face a unique revenue management challenge: non-covered cosmetic services require either an Advance Beneficiary Notice (ABN) for Medicare patients or a clear patient financial responsibility protocol for all payers. Without a systematic ABN process, cosmetic claims result in denial-plus-billing-dispute situations that are expensive to resolve and occasionally result in write-offs that should have been collected upfront. Additionally, cosmetic procedures paid by patients directly require a separate fee schedule, payment collection workflow, and financial policy management that most generalist billing teams simply aren't equipped to handle.
These two billing worlds coexist in the same dermatology practice — but operate under entirely different rules, covered differently by insurance, billed through completely separate systems, and governed by distinct compliance requirements. ParaMed manages both with equal expertise.
Medical dermatology covers the diagnosis and treatment of skin disease — conditions with ICD-10 diagnosis codes, payer coverage policies, medical necessity requirements, and insurance claims. This is standard medical billing, but with a dermatology-specific CPT code set that requires specialty expertise to navigate correctly.
Technique-based biopsy CPT codes (11102–11107) plus pathology coordination. Separate billing for specimen processing, special stains, and immunohistochemistry when applicable.
11102 / 11103 / 11104 / 11106Cryosurgery, laser ablation, electrosurgery for actinic keratoses, warts, and malignant lesions. Code selection based on lesion type and quantity — each with distinct medical necessity requirements.
17000 / 17003 / 17110 / 17111UVB, PUVA, and PDT treatments — session-based billing with medical necessity requirements for psoriasis, eczema, vitiligo, and CTCL. Coverage criteria vary significantly by payer.
96910 / 96912 / 96913 / 96920Allergen testing panels (95044 per allergen) with interpretation and reporting. High-revenue service with specific NCCI rules on maximum reportable patch test units per session.
95044 / 95052 / 95056 / 95060Subcutaneous biologics (dupilumab, secukinumab, ixekizumab) administered in-office — separately billable using drug HCPCS codes plus administration codes. High-value service requiring prior authorization management.
J0222 / J3490 / 96372Cosmetic procedures are generally not covered by insurance — they require a completely different billing system: a separate cosmetic fee schedule, upfront patient payment collection, clear financial policies, and — for Medicare patients — ABN documentation for any service that could potentially be considered medically necessary under any circumstance.
Cosmetic Botox, Dysport, Xeomin for aesthetic purposes — non-covered, patient-pay. Separate from medically necessary botulinum toxin for hyperhidrosis (which IS separately billable to insurance with correct documentation).
Patient-Pay — J0585 for medical indication onlyHyaluronic acid, collagen stimulators, and synthetic fillers for facial contouring and volume restoration. Uniformly non-covered by insurance. Requires fee-for-service billing, consent documentation, and product cost tracking.
Patient-Pay — Flat fee schedule per product/areaCosmetic laser resurfacing, IPL, fractional laser, radiofrequency skin tightening. Non-covered (distinct from medically indicated laser treatment of vascular lesions, scars, and port wine stains — which have insurance coverage pathways).
Patient-Pay — Treatment package billingCoolSculpting, Kybella, SculpSure — non-surgical body contouring. Primarily patient-pay with specific package billing, consent, and pre/post documentation protocols.
Patient-Pay — Package and per-cycle billingSuperficial and medium-depth chemical peels performed for cosmetic skin improvement — non-covered. Distinct from medically indicated peels for actinic keratosis. Correct classification is essential for compliance.
Patient-Pay — Document indication clearlySelect any dermatology procedure category to explore specific CPT codes, reimbursement benchmarks, and the billing rules that determine whether your claims are paid at the maximum defensible level or quietly downgraded and denied.
Medical dermatology billing centers on the E/M framework, the 2019-revised biopsy code set, phototherapy session billing, and the complex management of biologic drug administration. The E/M + procedure same-day scenario — requiring Modifier -25 with supporting documentation — affects the majority of medical derm visits and is the highest-frequency billing error in the specialty.
Most common medical derm E/M level. When performed same day as any procedure, requires Modifier -25 and documentation of a separately identifiable evaluation beyond the pre-procedure assessment.
Shave, saucerize, curette, or scoop technique. Most common derm biopsy code post-2019 revision. 11103 is each additional lesion. Replaces deleted 11100 — critical to use current codes.
Excimer laser for psoriasis, eczema, vitiligo — coverage varies by payer. Documentation must establish medical necessity including failed topical therapy. Separate from cosmetic laser codes.
Biologic injection administration code — billed separately from the drug HCPCS code. When nurse or MA administers in-office biologic, both the drug (J-code) and administration (96372) are separately billable in non-facility settings.
For E/M + procedure same day, the note must document evaluation of a condition separate from the procedure indication, OR document that the E/M resulted in a new diagnosis or treatment decision beyond the pre-procedure assessment.
When multiple biopsies are performed, the first lesion uses the primary code (11102, 11104, or 11106 by technique), and each additional lesion in the same technique family uses the add-on code. Different technique biopsies on the same day use separate primary codes.
J-codes for biologics are billable in non-facility settings where the practice purchases and administers the drug. In facility settings, the facility bills the drug cost. Billing J-codes in a facility setting is duplicate billing — a high-priority OIG audit area.
Phototherapy claims require documentation of the clinical indication, prior treatment failures, and the treatment protocol. Missing prior-treatment-failure documentation is the leading cause of phototherapy LCD denials.
Surgical dermatology billing is driven by precision measurement. Excision codes (11400–11646) are selected based on the narrowest diameter of the excised specimen including margins — measured in centimeters. The anatomic location determines which code family applies. Destruction codes use quantity-based coding. Repair codes are selected based on total repair length.
Location and size both determine the code. 11421 = scalp/neck/hands/feet/genitalia, 0.6–1.0cm. 11401 = trunk/arm/leg, same size. Different codes, different reimbursement, for the same size lesion in different locations.
Malignant lesion excision codes (11600–11646) reimburse significantly higher than benign codes and require documentation of malignancy (biopsy report or clinical diagnosis) and the precise margin-inclusive measurement in the operative note.
17000 = first AK; 17003 = each additional 2–14 lesions (add-on); 17004 = 15+ lesions (single code, no add-ons). Correct sequencing of 17000 + 17003 x (N-1) is the only correct way to bill AK destruction for 2–14 lesions.
Repair codes are based on total length of closure (sum of all closures in same wound classification and anatomic location). Intermediate repair requires a layered closure technique — simple closure of a wound that only needed simple repair cannot be coded as intermediate.
The CPT code for excision is based on the narrowest diameter of the excised specimen inclusive of the margins taken. The operative note must state the margin-inclusive measurement. A 0.4cm AK excised with 0.2cm margins is a 0.8cm excision.
The same-size excision on the trunk (11401) vs. the face (11441) vs. the scalp (11421) uses different code families with different reimbursements. Location must be precisely documented — "left arm" is different from "left hand" for billing purposes.
When multiple wounds are repaired at the same session, add the lengths of closures of the same classification and the same anatomic site together to select the code. Do not bill multiple smaller repair codes for closures that should be summed — it's an NCCI violation.
Simple (primary) closure is included in all excision codes — never bill a separate simple repair code in addition to an excision code. Only separately complex repairs (flap or graft) are billable in addition to the excision code when performed due to wound complexity.
Mohs micrographic surgery is the highest-value and most complex billing scenario in all of dermatology. It requires simultaneous management of the surgical stage codes, the pathology component, and the reconstruction code — often on the same date of service. Mohs bills by stage: 17311 (first stage, head/neck/hands/feet/genitalia) or 17313 (first stage, trunk/extremities), plus 17312 or 17314 (each additional stage).
Includes up to 5 tissue blocks in the first stage. The first-stage code is used once per procedure regardless of the number of blocks — additional blocks beyond 5 in the first stage use add-on 17315.
Add-on code to 17311 for each additional stage. A 3-stage Mohs procedure on the nose bills as: 17311 + 17312 + 17312 (x2 add-ons). Stage count from the operative/pathology report must be explicit — do not estimate stages.
Flap reconstruction following Mohs — significantly higher reimbursement than simple linear closure. Requires documentation of defect size, flap design, and technique. Many Mohs surgeons under-bill reconstruction because billing teams default to simple closure for all post-Mohs repairs.
FTSG for Mohs defect reconstruction — includes donor site closure in the primary code. When the donor site requires separate complex repair, that repair is additionally billable. Graft harvest and recipient site preparation must be documented separately.
The Mohs stage count determines the billing directly — every additional stage is a separately billed add-on. The pathology report and operative note must explicitly state the number of stages performed, the number of tissue blocks per stage, and the final clear margin confirmation.
Unlike all other dermatologic surgery, the Mohs surgeon performs and bills both the surgical and pathological components. Do not separately bill pathology codes for Mohs specimens — they are included in the Mohs stage codes.
Post-Mohs reconstruction is separately billable. The reconstruction code must reflect what was actually performed — linear closure (simple repair), advancement flap (14XXX), rotation flap, FTSG (15XXX), or STSG. Defaulting to a simple closure code when a flap was performed significantly under-bills every such case.
When Mohs surgery and reconstruction are performed on separate dates, the reconstruction claim requires Modifier -58 indicating it was a related procedure during the post-operative period. Without -58, the reconstruction claim is denied as part of the Mohs global period.
Cosmetic dermatology billing is a distinct revenue management discipline — not insurance billing, but a combination of fee schedule management, upfront collection protocol, consent and financial policy documentation, and the critical compliance task of correctly distinguishing cosmetic services from medically necessary ones. Botulinum toxin injections for hyperhidrosis, laser treatment for medically significant vascular lesions, and reconstructive procedures for functional impairment all have insurance billing pathways.
Botulinum toxin for medically diagnosed hyperhidrosis — insurance-billable with diagnosis code L74.510 (primary hyperhidrosis, axilla). This is the medical indication code for Botox — completely distinct from cosmetic use. PA required from most plans.
Laser or other destruction of port wine stains, hemangiomas, and medically significant vascular birthmarks. These are medically covered — distinct from cosmetic laser treatment of rosacea or spider veins. Correct diagnosis code establishing medical nature is essential.
Upper blepharoplasty may be covered when documented dermatochalasis causes functional visual field impairment — requiring ophthalmologic documentation of field defect. Cosmetic upper blepharoplasty without visual impairment is patient-pay. Documentation determines coverage.
All cosmetic-indication injectables, fillers, body contouring, cosmetic laser, and aesthetic procedures require a separate dermatology cosmetic fee schedule, upfront payment collection, treatment consent documentation, and — for Medicare patients — a signed ABN before treatment.
For Medicare patients, an Advance Beneficiary Notice is required before any service that might be considered cosmetic by Medicare but is being performed with a potential medical indication. When in doubt, get an ABN signed — an unsigned ABN means you cannot collect from the patient if Medicare denies the claim.
Every procedure note for a service that has both cosmetic and medical applications must clearly document the clinical indication. "Patient requested cosmetic improvement" and "Treatment of medically significant condition" lead to entirely different billing pathways. The documentation, not the procedure, determines the classification.
Botulinum toxin for primary hyperhidrosis requires prior authorization from virtually every major commercial payer. Documentation requirements include: diagnosis with ICD-10 L74.510/L74.511/L74.512, documentation of failed antiperspirant therapy, and physician notes establishing functional impairment.
Cosmetic service packages must be administered through a separate cosmetic billing system with its own fee schedule, payment collection, and financial documentation — completely isolated from the insurance billing system to prevent accidental insurance submission of purely cosmetic services.
The Office of Inspector General consistently identifies dermatology as a high-risk specialty for billing irregularities. These are the five compliance risk areas that active OIG work plans and commercial payer Special Investigations Units focus on in dermatology — and the exposure level each carries for practices without specialty billing oversight.
Most audited dermatology billing pattern. Modifier -25 applied without documented separate E/M is the #1 OIG dermatology audit trigger.
Submitting cosmetic procedures to insurance under medical diagnosis codes. Both Medicare FIs and commercial SIUs actively investigate this pattern.
Billing more stages than documented in pathology. Both under-counting (revenue loss) and over-counting (fraud) are audited. Stage documentation must be airtight.
Billing a larger excision code than the documented measurement supports. The operative note measurement is the audit reference — it must match the CPT code exactly.
Incorrect use of 17000/17003/17004 AK destruction sequence. 17004 (15+ lesions) replaces 17000+17003 — using both is an NCCI violation and audit flag.
Click any service below to see exactly what our dermatology-certified billing team delivers on your account — in detail, with specific deliverables and the clinical context that makes each service essential to your practice revenue.
Dermatology coding requires simultaneous expertise in four distinct billing domains: medical dermatology E/M with Modifier -25 analysis, surgical dermatology with precise size- and location-based code selection, Mohs surgery stage counting and reconstruction coding, and cosmetic billing compliance. Our dermatology-certified coders work exclusively within the dermatology CPT universe — assigning the highest defensible code based on documentation review, flagging under-documentation gaps with provider query requests, and applying the correct modifiers for every procedure, every day. We apply current 2019+ biopsy codes, current excision code families, and up-to-date destruction quantity rules — never the deleted or outdated codes that trigger automatic rejection.
For dermatology, the documentation in the operative note and procedure report determines revenue more directly than in almost any other specialty — because measurements, technique, stage count, and clinical indication all flow directly from documentation to CPT codes to reimbursement. Our coders review every note for documentation completeness, flag deficiencies that would require a lower code than the procedure actually supports, and generate provider query requests when documentation can be corrected before claim submission. Over 90 days, this feedback loop demonstrably improves documentation quality across your practice — creating a permanent revenue lift as documentation consistently supports the highest appropriate code level.
The OIG publishes annual work plans that identify specific billing patterns under active investigation — and dermatology is consistently represented. Our compliance monitoring team reviews OIG work plan updates quarterly, tracking every dermatology-specific audit target and adjusting pre-submission review protocols accordingly. When the OIG announces a focus on Modifier -25 use in dermatology, we immediately implement a more rigorous -25 documentation review for all applicable claims. Proactive compliance monitoring means your practice isn't caught off-guard by an audit; it means you've already addressed the audit trigger before investigators arrive.
The compliance border between cosmetic and medical dermatology is a bright line — and crossing it creates serious consequences. Our compliance review includes quarterly sampling of all claims for services with both cosmetic and medical applications — verifying that each claim is correctly classified, that the diagnosis code supports the billing pathway chosen, and that Medicare ABN documentation is in place where required. We also maintain a practice-specific crosswalk of every service in your cosmetic service menu against its potential insurance-covered counterpart, ensuring that cosmetic services are consistently recognized and never accidentally submitted to insurance.
Appealing a denied dermatology claim requires the same specialty knowledge that coding it required. A Modifier -25 denial needs a clinical argument demonstrating that the E/M addressed a condition separate from the procedure's indication — citing the documentation that supports it. An excision size denial needs an appeal that references the operative note measurement and explains the margin-inclusive measurement standard. A phototherapy medical necessity denial needs an LCD-aligned argument presenting the prior treatment failures and clinical criteria required for coverage.
When cosmetic service payments are disputed — either because insurance was inadvertently submitted or because patient financial responsibility is contested — our team manages the resolution process. This includes correcting erroneous insurance submissions for cosmetic services, managing patient balance billing disputes for cosmetic services that were clearly non-covered and properly documented as patient responsibility, and coordinating the ABN process for any cases where Medicare coverage is ambiguous. Our goal is zero-balance resolution on every recoverable claim — across both the insurance billing and patient-pay sides of your dermatology practice.
Cosmetic dermatology services require a completely separate billing infrastructure from your insurance-based medical billing — a distinct cosmetic fee schedule, upfront payment collection workflow, treatment package billing, and financial policy documentation. ParaMed establishes and manages this cosmetic billing system as a distinct operational layer within your practice — ensuring that cosmetic revenue is captured, collected, and tracked separately from insurance revenue, with no risk of cosmetic procedures accidentally entering the insurance claims pipeline.
Every dermatology practice offering cosmetic services needs a clear, written financial policy that patients acknowledge before treatment — establishing that cosmetic services are not covered by insurance and are the patient's financial responsibility. For Medicare patients receiving any service that could conceivably be considered medically necessary, an ABN must be executed before service delivery. Our team manages ABN generation, tracking, and documentation for every applicable Medicare patient encounter — ensuring that your practice has the legal authority to collect from the patient when Medicare denies a service.
Dermatology practices generating revenue across medical, surgical, Mohs, and cosmetic service lines need performance reporting that reflects that complexity. Our monthly dermatology performance reports break down revenue, denial rates, and collection rates by service line — giving practice administrators and physician owners the visibility to understand exactly which service lines are performing and which are underperforming. Reports include revenue per procedure category, Mohs revenue per case (surgical + reconstruction combined), cosmetic collection rate vs. scheduled procedures, and denial rate by procedure type.
Monthly compliance metrics included in every dermatology report: Modifier -25 usage rate with documentation compliance confirmation, cosmetic-to-medical classification accuracy rate, excision code accuracy against documented measurements, and Mohs stage count reconciliation. When any compliance metric shows a deviation from baseline, our team identifies the root cause and addresses it in the following billing cycle — keeping your practice in continuous OIG audit readiness without requiring a separate compliance program investment.
Each major payer approaches dermatology coverage, prior authorization, and medical necessity differently — especially for high-value services like phototherapy, biologic administration, and cosmetically adjacent procedures.
High-audit-risk payer for dermatology — Modifier -25 and cosmetic procedure billing are actively monitored. MACs publish LCDs for specific dermatology services including phototherapy and destruction procedures.
Follow Medicare coding rules but have independent PA requirements — often more restrictive than traditional Medicare for high-cost dermatology services including phototherapy and specialty drug administration.
Dermatology coverage varies significantly between commercial plans — cosmetically adjacent procedures have inconsistent coverage, and biologic prior authorization requirements are among the most stringent of any specialty.
UHC has extensive dermatology-specific medical policies covering cosmetically adjacent procedures, biologics, and phototherapy — with one of the most detailed step-therapy requirement systems for dermatologic biologics.
Medicaid dermatology coverage varies significantly by state — many state programs cover basic medical dermatology but have limited or no coverage for specialty biologics, phototherapy, or any cosmetically adjacent procedures.
The self-pay and cosmetic patient population requires a completely different approach to financial management — fee schedule setting, package pricing, payment collection at time of service, and financial policy communication.
Every performance metric below is tracked, documented, and reported to every ParaMed dermatology client monthly — compared against the baseline at engagement start so you can see exactly what's changed.
Real performance metrics maintained across our dermatology billing client base — tracked and reported monthly.
Get My Free AuditEvery dermatology practice onboarding begins with a free specialty audit that identifies your specific revenue gaps. We build your account protocol, configure compliance rules for your exact service mix, and submit your first claims within 10–12 business days of engagement start.
We code a representative sample of your recent claims — identifying excision size errors, missed Mohs reconstruction codes, deleted biopsy codes, and Modifier -25 documentation gaps — with a precise monthly revenue impact estimate for each finding.
We document your complete service mix — medical, surgical, Mohs, cosmetic — and build your practice-specific billing protocol: cosmetic vs. medical classification rules, -25 modifier documentation requirements, excision measurement standards, and payer-specific coverage rules for your exact payer mix.
We establish your separate cosmetic billing infrastructure — fee schedule, upfront collection protocol, ABN templates for Medicare patients, financial policy documentation, and treatment package billing framework. Cosmetic and insurance billing are configured as completely separate workflows from Day 1.
First dermatology claims submitted within 24 hours of receiving completed documentation. Every claim passes through our dermatology-specific pre-submission review — including Modifier -25 documentation check, excision size verification, Mohs stage count reconciliation, and NCCI edit compliance.
First monthly performance dashboard delivered — service line revenue breakdown (medical, surgical, Mohs, cosmetic), denial rate by procedure type, Modifier -25 compliance confirmation, and comparison against pre-engagement audit baseline.
Real outcomes from dermatologists, Mohs surgeons, and cosmetic dermatology practice administrators who replaced generalist billing with ParaMed's dermatology-specialist team.
"The free audit ParaMed did found that we were billing post-Mohs reconstruction as simple closure on virtually every case. Our billing team defaulted to 12001 regardless of whether we'd done a flap or a graft — they didn't know the difference mattered. ParaMed recoded a sample of 90 days of Mohs cases and found $38,000 in under-billed reconstruction revenue. In just 90 days. After they took over, our average revenue per Mohs case increased by 41%. For a practice doing 15–20 Mohs cases per week, that number compounds fast."
"We had an OIG audit triggered — partly because our Modifier -25 usage rate was a statistical outlier. We were applying it on virtually every E/M + procedure visit without documentation review. ParaMed came in during the audit response, helped us document and defend the claims under review, and then completely rebuilt our Modifier -25 protocol going forward. We now have documentation language in every note that specifically supports -25 when it's applied. Our modifier usage rate is still appropriate for a dermatology practice — but now it's defensible, documented, and compliant."
"Our cosmetic billing was a complete mess — cosmetic Botox was occasionally getting submitted to insurance by accident, our ABN process for Medicare patients was nonexistent, and we had no real separation between cosmetic and medical billing workflows. ParaMed built a completely separate cosmetic billing system, implemented ABN documentation for every applicable Medicare encounter, and created a financial policy process that patients now sign before every cosmetic treatment. We haven't had a single cosmetic billing compliance issue since. That compliance protection alone is worth more than the billing fee."
Tell us about your practice. We respond within one business day with a scheduled audit time — and within 48 hours of that, you'll have a written report showing exactly what your current billing is leaving behind across every service category.
We code a sample of recent excisions and surgical procedures — comparing our size-based and location-based code selection to what was actually billed, and quantifying the monthly revenue difference.
We identify every Mohs case where reconstruction was billed as simple closure instead of the correct flap or graft code — and calculate the per-case and monthly reconstruction revenue recovery opportunity.
We review your current cosmetic vs. medical classification process, ABN documentation, and cosmetic billing separation — identifying compliance exposure areas and the specific risks they create.
Every finding is documented in a written report with specific dollar estimates per revenue category and compliance risk ratings — giving you a concrete ROI projection before any commitment is required.
"The audit took less than 48 hours and found $41,000 per month in recoverable revenue — $27,000 from Mohs reconstruction codes alone. I signed the contract before the audit report was even finished. Best decision I've made for this practice in years."— Dr. Rachel, Surgery Group, TX
No cost. No commitment. A clear, written picture of what your practice is leaving on the table — across medical, surgical, Mohs, and cosmetic billing.
Covering: Medical derm, Surgical derm, Mohs surgery, Cosmetic billing, Biologic administration, Phototherapy
From the precise margin-inclusive measurement of a complex excision to the stage-by-stage billing of a multi-stage Mohs procedure to the complete cosmetic billing compliance system your practice needs — ParaMed's dermatology-certified billing team handles it all. Every code. Every modifier. Every compliance requirement. Every day.
Trusted by Practices Across US — Feedback from providers who rely on ParaMed for smarter Medical Billing.
